… for the last available antifibrotic treatment episode in patients who were treated with
pirfenidone followed by nintedanib, or vice versa, during follow-up. All patients with a follow-up …

… We found that use of antifibrotic therapy was associated with … for antifibrotic drugs extending
survival in patients with IPF by … be attributed to the use of antifibrotic therapy. Our findings are …

… Licensed treatment options for IPF are pirfenidone and nintedanib. The aim of this study
was to assess the impact of antifibrotic therapy in patients with IPF with preserved lung function …

… a survival difference between patients treated with corticosteroids for ≥ 6 months and patients
who were not or treated … AF drugs are associated with a survival benefit in IPF and cannot …

… Antifibrotic treatment significantly … antifibrotic treatment may reduce the risks of all-cause
mortality, hospitalisation, acute exacerbation, and mortality after acute exacerbation in patients …

… with IPF for > 4 months after diagnosis before initiating treatment. c. Physicians who initiated
antifibrotic treatment within 4 months of diagnosis in the majority of patients with IPF. NICE, …

… This study revealed evidence of the effectiveness of antifibrotic treatment on reducing
hospitalization and death among older patients with advanced age (ie, >80 years), which is a …

… had better survival compared with those who did not receive treatment but this … survival in
the entire IPF patient population as well as in patients who had received antifibrotic treatment. …

… of antifibrotic drugs (pirfenidone or nintedanib) are associated with improved survival of IPF
patients in the era of antifibrotic … Thus, we propose that antifibrotic treatment for IPF should be …

… disease, resulting in a delay in diagnosis and unavoidably to a late starting of antifibrotic
treatments. Other patients may show a more rapid progression of the disease, and in some, the …